These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses. Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, Lee WJ, Kang B, Lee CK, Lee MG, Chung HC, Choi HJ, Park YN. Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649 [Abstract] [Full Text] [Related]
3. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. Lamarca A, Barriuso J, McNamara MG, Valle JW. J Hepatol; 2020 Jul; 73(1):170-185. PubMed ID: 32171892 [Abstract] [Full Text] [Related]
4. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective. Neuzillet C, Artru P, Assenat E, Edeline J, Adhoute X, Sabourin JC, Turpin A, Coriat R, Malka D. Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342 [Abstract] [Full Text] [Related]
5. Systemic treatment of advanced or recurrent biliary tract cancer. Zhang W, Zhou H, Wang Y, Zhang Z, Cao G, Song T, Zhang T, Li Q. Biosci Trends; 2020 Nov 04; 14(5):328-341. PubMed ID: 32830166 [Abstract] [Full Text] [Related]
6. Current and emerging immunotherapeutic approaches for biliary tract cancers. Yuan ZG, Zeng TM, Tao CJ. Hepatobiliary Pancreat Dis Int; 2022 Oct 04; 21(5):440-449. PubMed ID: 36115807 [Abstract] [Full Text] [Related]
7. How I treat biliary tract cancer. Lamarca A, Edeline J, Goyal L. ESMO Open; 2022 Feb 04; 7(1):100378. PubMed ID: 35032765 [Abstract] [Full Text] [Related]
8. Current and emerging therapies for advanced biliary tract cancers. Kam AE, Masood A, Shroff RT. Lancet Gastroenterol Hepatol; 2021 Nov 04; 6(11):956-969. PubMed ID: 34626563 [Abstract] [Full Text] [Related]
9. Molecular-driven treatment for biliary tract cancer: the promising turning point. Persano M, Puzzoni M, Ziranu P, Pusceddu V, Lai E, Pretta A, Donisi C, Pinna G, Spanu D, Cimbro E, Parrino A, Liscia N, Mariani S, Dubois M, Migliari M, Scartozzi M. Expert Rev Anticancer Ther; 2021 Nov 04; 21(11):1253-1264. PubMed ID: 34551663 [Abstract] [Full Text] [Related]
10. Targeted therapy for biliary tract cancers. Faris JE, Zhu AX. J Hepatobiliary Pancreat Sci; 2012 Jul 04; 19(4):326-36. PubMed ID: 22318523 [Abstract] [Full Text] [Related]
11. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. Rizzo A, Federico AD, Ricci AD, Frega G, Palloni A, Pagani R, Tavolari S, Marco MD, Brandi G. Cancer Control; 2020 Jul 04; 27(1):1073274820983013. PubMed ID: 33356500 [Abstract] [Full Text] [Related]
12. The state of therapy modalities in clinic for biliary tract cancer. Chen W, Hu Z, Song J, Wu Y, Zhang B, Zhang L. Front Biosci (Landmark Ed); 2022 Jun 08; 27(6):185. PubMed ID: 35748261 [Abstract] [Full Text] [Related]
13. A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step? Aimar G, Paratore C, Zichi C, Marino D, Sperti E, Caglio A, Gamba T, De Vita F, Di Maio M. Explor Target Antitumor Ther; 2021 Jun 08; 2(5):448-464. PubMed ID: 36045702 [Abstract] [Full Text] [Related]
14. Current options and future directions of systemic therapy for advanced biliary tract cancer. Prete MG, Cammarota A, D'Alessio A, Zanuso V, Rimassa L. Explor Target Antitumor Ther; 2021 Jun 08; 2(5):416-433. PubMed ID: 36045701 [Abstract] [Full Text] [Related]
15. Biliary cancer: Utility of next-generation sequencing for clinical management. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. Cancer; 2016 Dec 15; 122(24):3838-3847. PubMed ID: 27622582 [Abstract] [Full Text] [Related]
16. Mutational spectrum and precision oncology for biliary tract carcinoma. Lin J, Cao Y, Yang X, Li G, Shi Y, Wang D, Long J, Song Y, Mao J, Xie F, Bai Y, Zhang L, Yang X, Wan X, Wang A, Guan M, Zhao L, Hu K, Pan J, Huo L, Lu X, Mao Y, Sang X, Zhang H, Wang K, Wang X, Zhao H. Theranostics; 2021 Dec 15; 11(10):4585-4598. PubMed ID: 33754015 [Abstract] [Full Text] [Related]
17. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma. Bath NM, Pawlik TM. Chin Clin Oncol; 2023 Feb 15; 12(1):5. PubMed ID: 36922354 [Abstract] [Full Text] [Related]
18. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. Rizzato M, Brignola S, Munari G, Gatti M, Dadduzio V, Borga C, Bergamo F, Pellino A, Angerilli V, Mescoli C, Guido M, Rearden J, Gringeri E, Cillo U, Dei Tos AP, Zagonel V, Loupakis F, Lonardi S, Fassan M. Eur J Cancer; 2022 May 15; 166():165-175. PubMed ID: 35303508 [Abstract] [Full Text] [Related]
19. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives. Ten Haaft BH, Pedregal M, Prato J, Klümpen HJ, Moreno V, Lamarca A. Eur J Cancer; 2024 Mar 15; 199():113564. PubMed ID: 38266541 [Abstract] [Full Text] [Related]
20. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Athauda A, Fong C, Lau DK, Javle M, Abou-Alfa GK, Morizane C, Steward K, Chau I. Cancer Treat Rev; 2020 Jun 15; 86():101998. PubMed ID: 32203843 [Abstract] [Full Text] [Related] Page: [Next] [New Search]